Food Supplements and Medical Foods in Brain Function: A Mechanism-Anchored Evidence Map

Abstract

Background:

The market for food supplements and medical foods targeting brain function is expanding rapidly, yet consumers and clinicians lack a clear framework for evaluating ingredients based on specific biological mechanisms and the quality of supporting evidence. Reviews often group ingredients by commercial category rather than by their molecular or systems-level targets.

Objective:

This narrative review aims to create a mechanism-anchored evidence map for common food supplements and medical foods purported to support brain function. We organize ingredients according to a four-domain biological framework: (1) Cognitive Performance & Neuroplasticity, (2) Stress Resilience, Anxiolysis & Sleep Architecture, (3) Cellular Energy & Mitochondrial Function, and (4) Convergence Nodes (cross-domain master regulators).

Methods:

A broad literature search was conducted across multiple academic databases and web sources for each of the four domains. Sources were screened for relevance to brain function, the presence of human evidence (or strong mechanistic data), and the testing of a specific, named ingredient. A curated list of ingredients was then subjected to targeted enrichment searches for high-quality evidence (meta-analyses, systematic reviews, and randomized controlled trials). Each ingredient was profiled for its mechanism, clinical outcomes, evidence level, and safety.

Results:

Evidence was mapped for numerous ingredients across the four domains. Domain 1 (Cognition) is supported by ingredients like Ginkgo biloba (EGb 761) and Bacopa monnieri, which have strong meta-analytic evidence for specific cognitive endpoints[1, 2]. Domain 2 (Stress/Sleep) features ingredients such as L-theanine, Saffron, Lavender oil (Silexan), and Vitamin D, all with strong evidence for anxiety or sleep outcomes[3–6]. Domain 3 (Energy) is best represented by Creatine monohydrate for memory and exogenous ketones for cognitive performance[7, 8]. Domain 4 (Convergence) includes Folate/L-methylfolate, which has strong evidence as an adjunct therapy for depression[9, 10]. Many popular ingredients were found to have limited evidence or "NO PROOFS TO DATE" for specific brain-related endpoints.

Conclusions:

A mechanism-anchored approach provides a structured way to evaluate the scientific basis for using food supplements and medical foods for brain function. While several ingredients have robust evidence for specific, targeted outcomes, many others lack rigorous human data. This map highlights both the most promising interventions and critical gaps in the research, guiding more discerning use and future investigation.

Keywords:

nootropic, nutraceutical, cognitive enhancement, food supplement, medical food, brain health, evidence-based, mechanism of action

Introduction

The proliferation of food supplements, nutraceuticals, and medical foods marketed for brain health presents a significant challenge for consumers, clinicians, and researchers. Unlike regulated pharmaceuticals, these products are often evaluated based on broad, ill-defined categories like "memory support" or "stress relief," with little reference to specific, plausible biological mechanisms of action. This lack of a structured, mechanism-anchored framework makes it difficult to assess the quality of evidence, compare disparate ingredients, and make informed decisions. A more rigorous approach is needed to move beyond category-level reviews and evaluate each ingredient based on its specific molecular and systems-level targets within the brain.

This review organizes the evidence according to a four-domain mechanistic map designed to connect molecular targets with observable brain-function outcomes. The domains are: (1) Cognitive performance & neuroplasticity, targeting neurotransmitter synthesis, neurotrophic factors, cerebrovascular support, and membrane integrity; (2) Stress resilience, anxiolysis & sleep architecture, focusing on the HPA axis, GABAergic/serotonergic systems, and circadian machinery; (3) Cellular energy, mitochondrial function & physical endurance, which covers the electron transport chain, NAD+ metabolism, and antioxidant defense systems crucial for the brain's high metabolic demand; and (4) Convergence nodes, which are cross-domain master regulators like BDNF, NF-κB, AMPK, mTOR, Nrf2, the methylation cycle, and the gut-brain axis that integrate signals from multiple pathways.

For every ingredient surveyed, this manuscript explicitly records two key pieces of information: (i) which target(s) on the mechanism map it plausibly engages, and (ii) the highest-quality human evidence available for its efficacy and safety. This includes the explicit labeling of ingredients with "no proofs to date" when rigorous human clinical trial evidence is absent, providing a transparent assessment of the current state of the science.

Methods

This narrative review employed a structured, multi-phase process to identify, evaluate, and synthesize the evidence for food supplements and medical foods related to brain function.

The initial search strategy was designed for broad recall, utilizing multiple academic database queries (e.g., PubMed, Google Scholar) and targeted web searches for each of the four mechanistic domains. Queries combined terms for ingredients (e.g., "nootropic," "adaptogen," "psychobiotic"), mechanisms (e.g., "BDNF," "HPA axis," "mitochondria"), and study types (e.g., "randomized controlled trial," "meta-analysis").

Sources were then screened against three primary criteria. The source had to be: (1) Brain-function relevant, concerning an ingestible compound tested for outcomes related to cognitive, mental, sleep, stress, or neurological function, or a mechanism supporting these functions; (2) Provide human evidence or strong mechanistic data, such as a randomized controlled trial (RCT), meta-analysis, systematic review, or a preclinical study explicitly linking an ingredient to a molecular target; and (3) Name a specific, identifiable ingredient or standardized extract.

Following this broad discovery phase, a curated list of canonical ingredients was generated. Each ingredient on this list was then subjected to a per-ingredient enrichment search, specifically targeting the highest levels of evidence, such as meta-analyses and systematic reviews of RCTs.

The evidence for each ingredient was synthesized and scored according to a rubric: Strong (multiple meta-analyses and/or numerous confirmatory RCTs), Moderate (multiple RCTs with consistent direction of effect), Limited (single RCT or a small number of inconsistent studies), Mechanistic/preclinical only (human efficacy data is absent), and NO PROOFS TO DATE (no rigorous human evidence found in the search).

The final data, including mechanism, evidence level, clinical outcomes, and safety notes, are compiled in a master evidence table provided as Appendix A to this manuscript.

Results

Domain 1 — Cognitive Performance and Neuroplasticity

Domain 1 ingredients are selected using the mechanistic map because most measurable, near-term “brain function” endpoints in humans (attention, memory, executive function, dementia scales, and functional status) are plausibly influenced by a limited set of convergent biological levers: (1) neurotransmitter precursor supply and signaling (especially cholinergic and catecholaminergic tone), (2) neuronal membrane and synapse substrate availability, and (3) neurotrophic and vascular support that can modulate plasticity and cerebral perfusion. The cholinergic lever is represented by compounds described as precursors for acetylcholine (ACh) biosynthesis and/or neuronal membrane phospholipids, such as phosphatidylcholine and CDP-choline (citicoline)[11–13]. A catecholamine lever is represented by L-tyrosine, which is explicitly described as a precursor to dopamine and norepinephrine and is proposed to buffer cognition under demanding conditions[14]. Neurotrophic signaling is a second major rationale in this domain because some interventions show biomarker shifts in neurotrophic pathways (e.g., increased circulating pro-BDNF with Hericium erinaceus, and increased serum BDNF in RCT meta-analysis for curcumin)[15, 16]. Finally, several Domain 1 candidates are motivated by vascular and metabolic support signals linked to cognition, including claims of increased cerebral blood flow (omega-3 sources) and blood-flow/angiogenesis mechanisms (cocoa flavanols)[9, 17].

Citicoline (CDP-choline)

Citicoline (CDP-choline) is described as a precursor essential for phosphatidylcholine synthesis and as releasing cytidine and choline after administration, with review literature stating it “activates the biosynthesis of structural phospholipids in the neuronal membranes” and is “essential for acetylcholine biosynthesis.”[12, 13, 18] In cognitive impairment populations, a systematic review/meta-analysis reported that citicoline improved cognitive status with pooled standardized mean differences ranging from 0.56 to 1.57 (in sensitivity analyses), while also noting that overall study quality was poor[19]. In acute traumatic brain injury, a systematic review/meta-analysis of 11 clinical studies (n=2771) reported a higher rate of independence with citicoline (RR 1.18, 95% CI 1.05–1.33)[20]. Effective dosing across clinical trials has been summarized as 500–2,000 mg/day, and the intervention was reported as well tolerated with “no safety concerns” in the TBI meta-analysis[20–22].

Verdict: Strong (meta-analyses + multiple clinical studies, but with quality concerns in cognition trials)[19].

Alpha-GPC

Alpha-GPC is described as a choline-containing phospholipid used to treat cognitive impairments and is characterized as a precursor to acetylcholine biosynthesis (with additional “neuroprotective signaling” claims in review text)[23, 24]. A systematic review/meta-analysis that included seven RCTs reported significant improvements on cognition, function, and behavior when alpha-GPC was used in combination with donepezil (e.g., cognition MD 1.72, 95% CI 0.20 to 3.25)[25]. In a 12-week multicenter randomized placebo-controlled trial in mild cognitive impairment (n=100), 600 mg/day alpha-GPC led to a 2.34-point decrease on ADAS-cog relative to placebo and reported no serious adverse events with no discontinuations due to adverse events[23].

Verdict: Moderate (multiple RCTs; some strongest quantitative effects are in combination therapy)[25].

Choline (bitartrate / chloride)

Choline (bitartrate / chloride) is explicitly described as a precursor of both betaine and acetylcholine and is therefore hypothesized to influence cognitive outcomes[3]. However, a review concludes that “high-quality (intervention) studies are lacking” for adult cognition outcomes[3]. In a randomized, double-blind, placebo-controlled trial in healthy postmenopausal women, 1 g/day choline bitartrate significantly increased circulating free choline and betaine and produced a reduction in plasma total homocysteine that approached statistical significance at week 6 (P=0.058), with no effect on plasma lipids in the abstract[26]. A key caution raised in review text is that possible harmful cardiometabolic effects require careful evaluation[3].

Verdict: Limited (biochemical RCT evidence exists, but adult cognition trials are described as lacking high quality)[3].

Phosphatidylserine (PS)

Phosphatidylserine (PS) is described as an essential component of the cerebral cortex associated with cognitive function[27]. A systematic review/meta-analysis (nine studies including five RCTs) concluded that PS had a positive effect on memory in older adults with cognitive decline, and summarized that PS “appears to improve age-associated cognitive decline, especially memory,” with PS doses varying from 100–300 mg/day across included studies[27]. In a randomized trial in non-demented elderly with memory complaints, PS-DHA at 300 mg PS/day for 15 weeks was reported as safe and well tolerated without negative effects in tested parameters[28]. In a separate small trial in elite shooters, PS supplementation decreased panic scores and altered cortisol-related measures (with improved sleep quality trends that did not reach statistical significance)[29].

Verdict: Moderate (multiple RCTs with supportive meta-analysis for memory; some ancillary stress/sleep signals in small studies)[27].

Phosphatidylcholine (PC)

Phosphatidylcholine (PC) is presented as used in brain-disease trials because it functions as a precursor for ACh biosynthesis and as an integral part of neuronal membranes[11]. In a double-blind RCT in pregnancy (n=140), 750 mg/day phosphatidylcholine from 18 weeks gestation through 90 days postpartum was well tolerated, but infant cognitive outcomes at 10 and 12 months did not differ significantly between groups (language, global development, and memory measures)[30]. Preclinical findings in mice with dementia suggest PC administration increased brain choline/ACh and improved memory, but this does not substitute for direct adult cognition efficacy evidence in humans[31].

Verdict: Limited (human RCT shows tolerability but null infant outcomes; adult cognition evidence not established in provided sources)[30].

Omega-3 EPA/DHA (fish oil)

Omega-3 EPA/DHA (fish oil) are described as important for brain development and cognitive performance, with DHA characterized as the dominant omega-3 in the brain that impacts neurotransmitters and brain function[9, 10]. In a systematic review/meta-analysis of randomized trials of fish oil supplementation in pregnant and/or breastfeeding women, 11 trials were included and no significant association was found between DHA/EPA supplementation and assessed cognitive parameters in children[10]. Other RCT-focused review text states ingestion of omega-3 fatty acids increases learning, memory, cognitive well-being, and blood flow in the brain, illustrating how conclusions can differ depending on population and study set[9].

Verdict: Moderate (multiple RCTs and meta-analyses exist, but cognition effects are inconsistent in the provided evidence)[10].

Bacopa monnieri (bacosides)

A systematic review evaluating whether Bacopa enhances cognition in humans reported that across studies Bacopa improved performance on 9 of 17 tests in memory free recall, while finding little evidence of enhancement in other cognitive domains; trials were typically conducted over 12 weeks with 300–450 mg/day extract in included studies[32]. A meta-analysis of eligible RCT participants reported improved cognition with shortened Trail B test performance and decreased choice reaction time after chronic dosing of standardized extracts (≥12 weeks)[2]. In a separate RCT in mild cognitive impairment, there was no statistically significant difference between groups for sleep quality overall score (and the dosing described was 160 mg extract for 2 months), suggesting that not all populations and outcomes show benefit[7].

Verdict: Strong (meta-analytic RCT evidence for specific cognitive measures, with domain-specific rather than broad-spectrum effects)[2, 32].

Ginkgo biloba (EGb 761)

Systematic reviews/meta-analyses in dementia evaluate EGb 761 using validated cognition, activities of daily living (ADL), and global assessments[1]. In pooled analyses, change scores significantly favored EGb 761 versus placebo for cognition, ADL, and global rating (e.g., cognition SMD −0.52, 95% CI −0.98 to −0.05; P=0.03), and a separate meta-analysis highlights that benefits are mainly associated with EGb 761 at 240 mg/day over 22–24 weeks[1, 33, 34]. Safety outcomes in the meta-analyses report no important safety concerns and similar adverse-event frequency versus placebo[1, 33, 35].

Verdict: Strong (multiple RCTs and meta-analyses with consistent dementia-relevant endpoint improvements and acceptable tolerability)[1, 33].

Lion's Mane (Hericium erinaceus)

Reviews describe Hericium erinaceus as being tested for cognitive decline/Alzheimer’s disease and mental health conditions, and one RCT reported that eight weeks of oral supplementation decreased depression, anxiety, and sleep disorders while increasing circulating pro-BDNF (without significant change in circulating BDNF)[15, 36]. A review that included one RCT and one pilot clinical trial reported a combined weighted mean increase of 1.17 in MMSE scores in the intervention group, but also noted mixed findings across symptom domains in other summaries[36, 37]. Reported side effects across reviews were uncommon and typically mild (e.g., gastrointestinal discomfort), though potential effects such as headache and allergic reactions are mentioned[4, 37].

Verdict: Moderate (multiple controlled trials exist with mixed cognitive and mood signals; evidence base remains relatively small)[37].

Huperzine A

Meta-analytic summaries report that compared with placebo, Huperzine A improved cognitive function as measured by MMSE at 8–16 weeks, with ADL also favoring Huperzine A at multiple time points in Alzheimer’s disease populations[38]. A systematic review included 20 RCTs (n=1823) but noted that most included trials had a high risk of bias, which limits confidence in effect estimates despite positive findings[38]. Safety summaries indicate adverse events were mostly cholinergic in nature and no serious adverse events were reported in the included trials described in meta-analysis abstracts[38, 39].

Verdict: Moderate (many RCTs exist, but high risk of bias reduces certainty)[38].

Vinpocetine

A Cochrane review of double-blind randomized trials in dementia (total n=583) concluded that evidence for vinpocetine’s benefit was inconclusive and did not support clinical use, while noting that some benefit was associated with 30 mg/day and 60 mg/day but with small numbers treated for ≥6 months[40]. In a separate pooled analysis cited in a systematic review, change in MMSE was better in the vinpocetine group than placebo (pooled WMD 0.92, 95% CI 0.02–1.82)[41]. Adverse effects were inconsistently reported in dementia trials and intention-to-treat data were not available for any of the trials in the Cochrane summary[40].

Verdict: Moderate (multiple RCTs exist, but the highest-level dementia review concludes evidence is inconclusive)[40].

Souvenaid / Fortasyn Connect (medical food)

Souvenaid / Fortasyn Connect (medical food) is described as a medical food designed to support synapse synthesis in Alzheimer’s disease, and its Fortasyn Connect formulation includes precursors and cofactors for neuronal membrane formation (e.g., uridine monophosphate, choline, phospholipids, EPA/DHA, and vitamins and selenium)[8]. In the S-Connect 24-week double-masked RCT in 527 mild-to-moderate AD patients on standard AD medications, cognition assessed by ADAS-cog declined in both groups with no significant difference between active and control (difference 0.37 points; p=0.513)[8]. Safety reporting indicates no group differences in adverse-event rates and that Souvenaid was well tolerated alongside AD medications, with no serious adverse events observed in the systematic review summary[8, 42].

Verdict: Moderate (multiple RCTs exist with mixed findings; one large RCT shows null ADAS-cog effect in medicated mild-to-moderate AD)[8].

L-tyrosine

Tyrosine is explicitly described as a precursor to dopamine and norepinephrine, and review synthesis reports that tyrosine loading can acutely counteract decrements in working memory and information processing under demanding conditions such as cognitive load or extreme weather[14]. Individual RCTs report improved vigilance/psychomotor outcomes (e.g., reduced lapses) and improved cognitive flexibility (reduced switching costs)[43, 44]. However, a systematic review also concludes the available evidence is insufficient to make confident recommendations for mitigating stress effects on performance, emphasizing heterogeneity and context dependence[45].

Verdict: Moderate (multiple trials with plausible acute effects in stress contexts, but synthesis-level uncertainty remains)[14, 45].

Centrophenoxine (meclofenoxate)

In elderly patients with Alzheimer-type senile dementia, a double-blind comparative randomized trial reported that prolonged treatment decreased psychogeriatric scores and improved multiple cognitive performance measures (attention, concentration, memory, IQ), with a neurometabolic complex containing meclofenoxate reported as significantly superior to meclofenoxate alone[46]. In another double-blind trial in older adults, 48% of the active group displayed improvements in memory functions compared with 28% of placebo after 8 weeks of centrophenoxine treatment at 2 g/day (as described in the study protocol)[5]. Preclinical findings in chronic cerebral hypoperfusion models report improved memory impairment and reduced oxidative/inflammatory mediator changes with oral centrophenoxine, but this is not direct human proof of mechanism or efficacy[47]. Verdict: Limited (small/older RCTs with positive signals; contemporary high-quality replication not shown in provided sources)[5].

Caffeine

Acute caffeine consumption in sleep-deprived/restricted settings shows meta-analytic improvements across cognitive domains, including improved attention response time and executive function (e.g., response time g=0.86; executive function g=0.35)[48]. The same body of evidence indicates caffeine can impair sleep, typically prolonging sleep latency and reducing total sleep time/efficiency and slow-wave sleep, with dose- and timing-response relationships reported[49]. Inter-individual sensitivity is supported by genetic association summaries linking ADORA2A variants to anxiety/sleep disturbance and CYP1A2 variants to cognitive function[50]. Verdict: Moderate (robust acute-performance evidence, counterbalanced by reliable sleep-disruption effects)[48, 49].

Domain 2 — Stress Resilience, Anxiolysis, and Sleep Architecture

Domain 2 ingredients are mapped to brain-function outcomes that emerge when stress systems, inhibitory neurotransmission, and circadian sleep–wake regulation are shifted in a clinically meaningful direction, as reflected in trials measuring perceived stress, anxiety severity, cortisol, sleep onset/quality, and next-day functioning. This domain is therefore mechanistically anchored to

1. HPA-axis and neuroendocrine stress-response modulation (e.g., adaptogens such as Rhodiola with explicit HPA-axis discussion, and magnesium’s stated involvement in HPA-axis regulation)[51, 52],
2. GABAergic modulation (e.g., valerian’s “adjustment of … GABA function,” hops’ GABAA receptor modulation, and kava’s GABA-related mechanisms)[53–55],
3. serotonergic precursors that influence mood and sleep biology (e.g., tryptophan and 5-HTP as serotonin precursors and 5-HTP conversion to serotonin in brain)[56–58], and
4. gut–brain axis interventions (psychobiotics and prebiotics) that act through neuromodulatory metabolites and inflammatory control relevant to stress and sleep phenotypes[59].

Rhodiola rosea (rosavins/salidroside)

Mechanistically, Rhodiola is described as modulating the HPA axis and neurotransmitter systems, with additional discussion of antioxidant pathways and mitochondrial function in the reviewed sources[51]. Clinically, systematic reviews summarize placebo-controlled RCTs and conclude Rhodiola “may alleviate symptoms of mild to moderate depression and mild anxiety” while enhancing mood, while also emphasizing that findings are “not definite” given limited experimental data, and that efficacy is described as “contradictory” in at least one review with high risk of bias/reporting flaws in included studies[60, 61]. Safety signals in these summaries are generally mild (“Only few mild adverse events were reported”)[62]. Verdict: Moderate.

Ashwagandha (Withania somnifera; KSM-66 / Sensoril)

Across human sleep trials summarized in a meta-analysis (5 RCTs; 400 participants), ashwagandha extract showed a small but significant improvement in overall sleep (SMD −0.59, 95% CI −0.75 to −0.42), with larger subgroup effects in adults diagnosed with insomnia and at doses ≥600 mg/day for ≥8 weeks; the same synthesis reports improvements in mental alertness on rising and anxiety level[63]. In stress/anxiety-focused meta-analysis, ashwagandha formulations reduced perceived stress (PSS MD −4.72), Hamilton Anxiety Scale (MD −2.19), and serum cortisol (MD −2.58) versus placebo, and some included studies reported mild-to-moderate adverse events[64]. Long-term serious adverse-effect data are explicitly described as limited, despite “No serious side effects” being reported in the sleep RCT evidence base summarized in that meta-analysis[63]. Verdict: Moderate.

L-theanine

In a systematic review/meta-analysis (18 included studies; N=897), L-theanine significantly improved several subjective sleep outcomes including sleep onset latency (SMD 0.15), daytime dysfunction (SMD 0.33), and overall subjective sleep quality score (SMD 0.43)[65]. A separate evidence synthesis reported that 200–400 mg/day “may assist in the reduction of stress and anxiety” in people exposed to stressful conditions[66]. In an RCT in adults without major psychiatric illness, 200 mg/day for 4 weeks decreased depression, anxiety, and PSQI scores, and improved verbal fluency and executive function scores versus baseline/placebo comparisons as reported in the trial abstract[67, 68]. Verdict: Strong.

Magnesium (glycinate / threonate / citrate)

Magnesium is described as “a key cation involved in neurotransmission, regulation of the HPA axis and sleep–wake control,” providing a map-consistent mechanistic rationale for stress and sleep endpoints across formulations[52]. For insomnia-related outcomes, a systematic review/meta-analysis identified three RCTs (151 older adults) and found a pooled reduction in sleep onset latency of 17.36 minutes versus placebo, while also noting moderate-to-high risk of bias and low to very low evidence quality[69]. For magnesium L-threonate specifically, RCTs in adults with sleep problems reported improvements versus placebo in objectively measured deep and REM sleep scores (Oura ring metrics) and multiple daytime measures (energy, productivity, mood, alertness), and reported it as safe and well tolerated; a separate RCT reported Magtein® improved overall cognitive performance with larger effects on working and episodic memory[70, 71]. Verdict: Moderate.

Glycine

Glycine is described as having roles in excitatory and inhibitory neurotransmission through NMDA-type glutamate receptors and glycine receptors, and a review proposes that a decline in core body temperature “might be a mechanism underlying glycine’s effect on sleep.”[72] However, one review notes that while longer-term glycine administration improved sleep in healthy populations, those studies had small sample sizes and high risk of bias, limiting confidence for sleep indications in this dataset[73]. In a separate psychiatric context, NMDA receptor co-agonists glycine and D-serine were effective for reducing negative symptoms of schizophrenia (fixed-effect SMD −0.66), while pooled cognitive functioning did not show a significant effect (random-effect WMD −2.79, p=0.11)[74]. Verdict: Limited.

GABA (exogenous)

A systematic review restricted to placebo-controlled human trials concluded that evidence is “limited” for stress and “very limited” for sleep benefits of oral GABA intake, while also stating that more studies are needed before inferences can be made[75]. Individual trials in the included set report domain-specific signals such as increased vigor-activity (POMS2) at week 6, changes in non-REM sleep stage 2 in an acute pre-bed crossover design, and improved habitual sleep efficiency (reduced PSQI) in a 90-day supplementation study that also observed increased HRV consistent with greater parasympathetic predominance[76–78]. Verdict: Limited.

Taurine

In a systematic review/meta-analysis of RCTs evaluating cognition, taurine (alone or with exercise training) did not show significant effects on cognitive scores, and the authors concluded evidence is insufficient to support efficacy for enhancing cognitive function[79]. A later systematic review summarized acute taurine dosing studies as showing, at best, small and inconsistent improvements in cognitive function (typically 1–3 g, up to ~50 mg/kg)[80]. Verdict: Moderate (multiple RCTs, largely null for cognition in available syntheses).

Domain 3 — Cellular Energy, Mitochondrial Function, and Physical Endurance

Domain 3 ingredients are selected using the mechanistic map because brain performance is tightly constrained by cellular energy supply (ATP generation), substrate flexibility, and mitochondrial redox balance, which can secondarily shape cognition, fatigue, mood, and stress tolerance. The included ingredients map onto

1. bioenergetic cofactors and electron-transfer/redox systems (e.g., CoQ10 as “intimately involved in energy production” and prevention of peroxidative damage)[81],
2. NAD+-precursor strategies (NR, NMN, and niacinamide as NAD+-linked approaches)[82, 83],
3. phosphocreatine buffering (creatine as a key component of brain bioenergetics)[84], and
4. alternative-fuel strategies (MCTs, caprylic triglycerides, and exogenous ketones to raise ketone bodies when glucose utilization is impaired)[85, 86].

Acetyl-L-carnitine (ALCAR)

Acetyl-L-carnitine (ALCAR) is positioned in Domain 3 because it “plays an essential role in intermediary metabolism” as an acetyl donor and by facilitating fatty-acid transfer into mitochondria during beta-oxidation, with additional reported neuromodulatory actions on brain energy/phospholipid metabolism and synaptic transmission[87, 88]. Consistent with this energy-centric rationale, meta-analyses of randomized trials report clinical signals in (a) depression (pooled across nine RCTs, ALC reduced depressive symptoms vs placebo/no intervention, SMD = -1.10)[89], and (b) MCI/mild Alzheimer’s disease (significant advantages vs placebo on integrated clinical/psychometric outcomes and clinician global change, with benefits evident by 3 months and increasing over time)[90]. Doses in the MCI/mild AD evidence base varied between 1.5–3.0 g/day, and tolerability was described as good across studies in that meta-analysis[90]. Verdict: Moderate. (Multiple RCTs with meta-analytic support for mood and MCI/mild AD outcomes.)[89, 90].

Axona (caprylic triglyceride medical food)

Axona (caprylic triglyceride medical food) targets Domain 3 via an alternative-fuel strategy: rather than improving glucose utilization, it seeks to supply ketone bodies that can cross the blood–brain barrier and provide an alternative energy source when glucose utilization is impaired[86, 91]. In the large double-blind RCT (NOURISH AD; 26 weeks; 413 patients stratified by APOE genotype), AC-1204 (caprylic triglyceride) did not improve the primary cognitive endpoint (ADAS-Cog11) and secondary outcomes “failed to detect any drug effects.”[92] Smaller studies reported mixed findings, including an overall negative statement (“did not improve cognitive function”) alongside a subgroup signal in some ApoE4-negative patients with baseline MMSE ≥ 14[93]. A practical consideration is gastrointestinal tolerability, which was “good, without severe gastrointestinal adverse effects” in one clinical intervention, and dose-titration from 10 to 40 g/day was used to reduce gastrointestinal adverse effects (with 40 g powder containing 20 g caprylic triglycerides)[93]. Verdict: Moderate (mixed/mostly negative for cognition in the largest RCT).[92, 93].

Coenzyme Q10 (ubiquinol / ubiquinone)

Coenzyme Q10 (ubiquinol / ubiquinone) is included for Domain 3 because it is described as having “bioenergetic and antioxidant activity” and being “intimately involved in energy production” and prevention of peroxidative damage to membrane phospholipids[81]. In humans, a meta-analysis of randomized trials in depression reported reduced depressive symptoms versus control (5 RCTs, 474 participants; SMD = -0.68), while showing no statistically significant benefit for fatigue based on only two trials[94]. Separate meta-analytic biomarker evidence indicates CoQ10 increased total antioxidant capacity and SOD and decreased malondialdehyde, consistent with a systemic antioxidant signal that aligns with Domain 3’s redox-defense node[95]. Verdict: Moderate. (Multiple RCTs with meta-analytic evidence for depressive-symptom improvement and antioxidant biomarker changes.)[94, 95].

Domain 4 — Convergence Nodes (cross-domain master regulators)

Domain 4 ingredients are prioritized because they target “convergence nodes” that plausibly influence multiple brain-relevant outcomes at once—e.g., neuroinflammation and oxidative stress (which can affect cognition and mood), vascular and metabolic factors (which can affect cerebral perfusion and energy availability), and one‑carbon/methylation pathways (which can affect monoamine neurotransmitter synthesis and related depressive symptoms). This cross-domain logic is consistent with multi-pathway mechanistic descriptions for botanicals such as ginseng (neuroinflammation, antioxidant capacity, mitochondrial metabolism, synaptic plasticity) and with human literature that links nutraceuticals to both cognitive endpoints (e.g., recognition memory) and systemic inflammatory markers (e.g., CRP, TNF-α)[96–99].

Panax ginseng

Mechanistically, ginseng is described as acting via multiple pathways relevant to convergence biology, including inhibition of neuroinflammation, enhanced antioxidant capacity, improved mitochondrial metabolism, and regulation of synaptic plasticity; it is also described as modulating HPA/HPG-axis signaling, neurotransmitters, and BDNF–TrkB pathways in the context of emotional regulation[96]. Clinically, a meta-analysis including 15 RCTs (analyzed n=671) reported a small but statistically significant improvement in memory (overall SMD=0.19, 95% CI 0.02–0.36), with a larger effect in “high dose” subgroup analyses (SMD=0.33, 95% CI 0.04–0.61), but no positive pooled effects for overall cognition, attention, or executive function outcomes[100]. A separate systematic review identified 9 randomized, double-blind, placebo-controlled trials meeting inclusion criteria, indicating multiple RCTs exist but with variable endpoints and results[101]. One example RCT administered 3 g/day Panax ginseng powder for 6 months and reported no serious adverse events; broader safety synthesis across trials likewise found “no serious adverse events,” while also noting that risk of bias was unclear in most studies[102, 103]. Evidence-level verdict: Moderate.

Magnolia bark (honokiol / magnolol)

The current evidence in the supplied sources is mechanistic and preclinical: honokiol and magnolol inhibited NMDA-stimulated superoxide production in neurons (a pathway involving NADPH oxidase) and inhibited IFNγ±LPS-induced iNOS expression, nitric oxide, and ROS production in microglial cells via a p‑ERK-dependent pathway[104]. A review explicitly states that more research is needed to improve bioavailability and to test these compounds in clinical studies, underscoring the absence of rigorous human efficacy evidence in this evidence pack[105]. Evidence-level verdict: Mechanistic-only.

Resveratrol (trans-resveratrol)

Human evidence is mixed across cognitive outcomes. A systematic review of intervention trials reported that across 10 included studies, some found improvements, some mixed findings, and others no effect, and pooled analyses showed statistically significant benefits for delayed recognition (pooled SMD=0.39, 95% CI 0.08–0.70; n=3 studies, n=166 participants) and negative mood (pooled SMD=-0.18, 95% CI −0.31 to −0.05; n=3 studies, n=163 participants)[97]. By contrast, another meta-analysis reported no significant effect on memory and cognitive performance assessed by auditory verbal learning tests, supporting endpoint-specific inconsistency[106]. Longer-term vascular–cognitive evidence includes a 24‑month randomized, placebo-controlled crossover trial in 125 postmenopausal women using 75 mg trans-resveratrol twice daily, which reported a “significant 33% improvement in overall cognitive performance” versus placebo and improvements in cerebrovascular measures (resting mean CBFV and CVR)[107]. Convergence-node plausibility is supported by meta-analytic reductions in systemic inflammation markers (CRP and TNF-α) after resveratrol supplementation, although one analysis noted possible CRP reduction without consistent changes in IL‑6 and TNF-α in that specific dataset[98, 99]. Evidence-level verdict: Moderate.

Discussion

This mechanism-anchored review provides a structured evaluation of food supplements and medical foods for brain function. The results highlight a clear hierarchy of evidence, with some ingredients backed by robust clinical data for specific outcomes, while many others rest on preclinical rationale or have inconsistent human trial results.

Cross-Domain Best-Evidence Picks

Based on the evidence synthesized in the Results section, a "best-evidence pick" can be identified for each of the four domains, representing the ingredient with the most consistent and high-quality human data for a relevant brain-function outcome:

• Domain 1 (Cognition): Ginkgo biloba extract EGb 761 demonstrates strong evidence from multiple meta-analyses of RCTs showing consistent benefits for cognition, activities of daily living, and global ratings in dementia, with a well-documented safety profile[1].
• Domain 2 (Stress/Sleep): Melatonin stands out with an extensive evidence base from numerous RCTs and meta-analyses demonstrating efficacy for improving sleep onset latency and total sleep time in various populations, with good tolerability[108].
• Domain 3 (Energy/Mitochondria): Creatine monohydrate has strong meta-analytic support from RCTs showing significant positive effects on memory performance, particularly in older adults, consistent with its role in brain bioenergetics[84, 109].
• Domain 4 (Convergence): Folate / L-methylfolate (5-MTHF) possesses strong evidence from multiple RCTs and meta-analyses supporting its use as an adjunct therapy to significantly reduce depressive symptoms, improve response rates, and increase remission rates[110].

Mechanism Convergence

Several ingredients demonstrate the principle of "mechanism convergence" by acting on multiple regulatory nodes simultaneously. For instance, omega-3 fatty acids (EPA/DHA) are involved in maintaining neuronal membrane integrity (Domain 1), have anti-inflammatory properties (Domain 4), and may influence neurotrophic factor signaling like BDNF (Domain 4)[9]. Similarly, creatine not only supports brain energy via the phosphocreatine system (Domain 3) but is also investigated for neuroprotective properties[84]. The B-vitamins (Folate, B6, B12) are central to the methylation cycle (Domain 4), which is critical for the synthesis of multiple neurotransmitters (Domain 1), the regulation of homocysteine (a vascular and neuronal health marker), and the production of SAMe[111, 112]. These multi-target actions may explain why certain supplements appear to have benefits across different functional domains.

Ingredients with NO PROOFS TO DATE

A critical finding of this review is the number of popular ingredients for which rigorous human evidence for brain-specific endpoints is lacking in the provided sources. For these ingredients, claims of cognitive or mood benefits are not yet substantiated by high-quality clinical trials. It is important to state plainly: No proofs to date. Examples include:

• Oral GABA supplementation: While mechanistically plausible, systematic reviews conclude there is very limited evidence for its efficacy on sleep or stress when taken orally[75].
• Spermidine: Human RCTs on cognition have yielded inconsistent results, with some showing benefit and others finding no significant effect on memory[113].

Uridine monophosphate, Pterostilbene, Palmitoylethanolamide (PEA): For these ingredients, no rigorous human trials supporting brain-related claims were identified in the initial evidence base.

Safety Considerations and Regulatory Status

Safety is a paramount consideration, and several ingredients have notable caveats. Kava, while showing moderate evidence for anxiolysis, carries a risk of hepatotoxicity, and regulatory bodies advise caution, routine liver function tests, and avoidance of alcohol[55]. Huperzine A, an acetylcholinesterase inhibitor, can cause cholinergic side effects, and its use requires caution, particularly in individuals taking other cholinergic agents[39]. These examples underscore the importance of evaluating not just efficacy but also the potential for adverse events and drug interactions, a process that is often less rigorous for supplements than for pharmaceuticals.

Limitations

This review has several limitations. The initial broad search and screening were based on titles and abstracts, which may have led to the exclusion of relevant studies. The evidence base is marked by significant heterogeneity in ingredient formulation (e.g., different Ashwagandha or Curcumin extracts), dosing, treatment duration, and the populations studied, making direct comparisons difficult. Publication bias, which favors positive results, likely affects the available literature. Finally, this review did not involve a de novo meta-analysis and relies on the data and quality assessments reported in existing systematic reviews. The absence of head-to-head trials for most ingredients means that relative efficacy cannot be determined.

Research Priorities

The mechanism-anchored map reveals several nodes where well-studied ingredients are lacking. For example, direct modulators of the glymphatic clearance system (e.g., targeting Aquaporin-4) represent a novel frontier with limited existing interventions. Similarly, while many ingredients claim antioxidant effects, few have been rigorously tested for their ability to specifically modulate neuronal redox signaling via targets like the Nrf2/Keap1 pathway in human cognitive trials. Future research should prioritize testing novel or existing compounds against these less-explored but biologically important targets to fill critical gaps in the evidence map.

Conclusions

This manuscript organizes the complex landscape of food supplements and medical foods for brain function into a coherent, mechanism-anchored framework. This approach moves beyond ambiguous marketing categories to evaluate ingredients based on their specific biological targets and the strength of the corresponding clinical evidence.

The results reveal a stark differentiation in the quality of evidence. A small number of ingredients, including Ginkgo biloba (EGb 761) for dementia, melatonin for sleep, creatine for memory, and L-methylfolate for adjunctive depression treatment, are supported by a substantial body of evidence from multiple RCTs and meta-analyses. A larger group of ingredients shows moderate or limited evidence, with promising but inconsistent results that warrant further, more rigorous investigation. Critically, a number of widely marketed ingredients have no robust human clinical trial data to support their use for brain-related outcomes.

By mapping ingredients to mechanisms and evidence, this review provides a valuable tool for clinicians, researchers, and consumers. It facilitates more informed and safer use of these products, highlighting compounds with the strongest scientific support for specific applications. Simultaneously, it illuminates the significant gaps in the literature, offering a clear guide for future research to build a more complete and reliable evidence base for enhancing and protecting brain function through nutrition.

Appendix A

Appendix A: Master Evidence Table (cross-reference Table 1 — delivered separately)

Note: The Master Evidence Table is a comprehensive appendix that provides detailed, row-by-row data for each of the 70+ ingredients analyzed for this manuscript. It is delivered as a separate, supplementary file to this document.

Appendix A — Supplementary Evidence Table

Supplementary source integrated: Appendix A — Master Evidence Table Brain-Function Ingredients.xlsx

References

1. [1] Bonvicini et al., 2023. Is Citicoline Effective in Preventing and Slowing Down Dementia?—A Systematic Review and a Meta-Analysis. Nutrients.
2. [2] Secades et al., 2023. Citicoline for the Management of Patients with Traumatic Brain Injury in the Acute Phase: A Systematic Review and Meta-Analysis. Life.
3. [3] Fioravanti & Yanagi, 2005. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database of Systematic Reviews.
4. [4] Secades & Frontera, 1995. CDP-choline: pharmacological and clinical review. Methods and Findings in Experimental and Clinical Pharmacology.
5. [5] Gromova et al., 2021. [Molecular and clinical aspects of the effect of cytidyndiphosphocholine on cognitive functions]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova.
6. [6] Secades, 2014. Citicoline for the Treatment of Head Injury: A Systematic Review andMeta-analysis of Controlled Clinical Trials. Trauma & Treatment.
7. [7] Qureshi & Endres, 2010. Citicoline: A Novel Therapeutic Agent with Neuroprotective, Neuromodulatory, and Neuroregenerative Properties.
8. [8] Fioravanti & Yanagi, 2000. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database of Systematic Reviews.
9. [9] Pase et al., 2012. The Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review of Randomized, Controlled Human Clinical Trials. Journal of Alternative and Complementary Medicine.
10. [10] Kongkeaw et al., 2014. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology.
11. [11] Delfan et al., 2024. Evaluating the effects of Bacopa monnieri on cognitive performance and sleep quality of patients with mild cognitive impairment: A triple-blinded, randomized, placebo-controlled trial. Explore.
12. [12] Gauthier & Schlaefke, 2014. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clinical Interventions in Aging.
13. [13] Bachinskaya et al., 2011. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®. Findings from a randomized controlled trial. Neuropsychiatric Disease and Treatment.
14. [14] Tan et al., 2014. Efficacy and Adverse Effects of Ginkgo Biloba for Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease.
15. [15] Savaskan et al., 2017. Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. International Psychogeriatrics.
16. [16] Riepe et al., 2025. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia – a meta-analysis of patient subgroups in randomised controlled trials. World Journal of Biological Psychiatry.
17. [17] Sagaro et al., 2023. Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease.
18. [18] Putri et al., 2026. L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. Neuropsychiatric Disease and Treatment.
19. [19] Jeon et al., 2024. Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial. BMC Geriatrics.
20. [20] Kerksick, 2024. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients.
21. [21] Sangiorgi et al., 1994. alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Annals of the New York Academy of Sciences.
22. [22] EunYoungKang et al. Effect of phosphatidylserine on cognitive function in the elderly: A systematic review and meta-analysis.
23. [23] Lu & An, 2018. PO-115 Effects of Phosphatidylserine on Mental States in Elite Shooters. Exercise Biochemistry Review.
24. [24] Vakhapova et al., 2011. Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension. BMC Neurology.
25. [25] Leermakers et al., 2015. Effects of choline on health across the life course: a systematic review. Nutrition reviews.
26. [26] Wallace et al., 2011. Choline supplementation and measures of choline and betaine status: a randomised, controlled trial in postmenopausal women. British Journal of Nutrition.
27. [27] Heras-Sola & Gallo-Vallejo, 2023. [Importance of choline during pregnancy and lactation: A systematic review]. Semergen.
28. [28] Roth et al., 2025. The Effect of Maternal Choline Intake on Offspring Cognition in Adolescence: Protocol for a 14-year Follow-Up of a Randomized Controlled Feeding Trial. JMIR Research Protocols.
29. [29] Lehner et al., 2020. Impact of omega-3 fatty acid DHA and EPA supplementation in pregnant or breast-feeding women on cognitive performance of children: systematic review and meta-analysis. Nutrition reviews.
30. [30] Dighriri et al., 2022. Effects of Omega-3 Polyunsaturated Fatty Acids on Brain Functions: A Systematic Review. Cureus.
31. [31] Growdon, 1987. Use of Phosphatidylcholine in Brain Diseases: An Overview.
32. [32] Cheatham et al., 2012. Phosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial. American Journal of Clinical Nutrition.
33. [33] Wang et al., 2026. Applications of Panax ginseng C. A. Mey. and its derivatives in cognitive and emotional dysregulation: A perspective from medicine-food homology. Journal of Traditional Chinese Medical Sciences.
34. [34] Zeng et al., 2024. Effects of Ginseng on Cognitive Function: A Systematic Review and Meta‐Analysis. Phytotherapy Research.
35. [35] Park et al., 2019. Cognition enhancing effect of panax ginseng in Korean volunteers with mild cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial. Translational and Clinical Pharmacology.
36. [36] Shergis et al., 2013. Panax ginseng in Randomised Controlled Trials: A Systematic Review. Phytotherapy Research.
37. [37] Cortonesi et al., 2023. Use of Hericium erinaceus as a potential therapeutic of mental disorders: a systematic review. Debates em Psiquiatria.
38. [38] Vigna et al., 2019. Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers?. Evidence-Based Complementary and Alternative Medicine.
39. [39] Menon et al., 2025. Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. Frontiers in Nutrition.
40. [40] Komoń et al., 2024. Neuroprotective and Cognitive Benefits of Hericium erinaceus: A Comprehensive Review of Recent Clinical Studies. Biuletyn Głównej Biblioteki Lekarskiej.
41. [41] Yang et al., 2013. Huperzine A for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. PLoS ONE.
42. [42] Tsai, 2019. Huperzine-A, a versatile herb, for the treatment of Alzheimer’s disease. Journal of the Chinese Medical Association.
43. [43] Chang-cheng, 2012. Meta-analysis of efficacy and safety of huperzine A for treatment of Alzheimer's disease. Chinese Journal of New Drugs and Clinical Remedies.
44. [44] Szatmári & Whitehouse, 2003. Vinpocetine for cognitive impairment and dementia. Cochrane Database of Systematic Reviews.
45. [45] Panda et al., 2022. Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Neurocritical Care.
46. [46] Valikovics et al., 2012. [Study of the effects of vinpocetin on cognitive functions]. Ideggyógyászati Szemle.
47. [47] Popa et al., 1994. Antagonic-stress superiority versus meclofenoxate in gerontopsychiatry (alzheimer type dementia). Archives of gerontology and geriatrics (Print).
48. [48] Pék et al., 1989. Gerontopsychological studies using NAI ('Nürnberger Alters-Inventar') on patients with organic psychosyndrome (DSM III, Category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial. Archives of gerontology and geriatrics (Print).
49. [49] Harris & Dowson, 1986. The effects of meclofenoxate on cognitive performance in elderly individuals with memory impairment: A placebo‐controlled study. International Journal of Geriatric Psychiatry.
50. [50] Clark & Landolt, 2017. Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials. Sleep Medicine Reviews.
51. [51] Kapellou et al., 2023. Genetics of caffeine and brain-related outcomes - a systematic review of observational studies and randomized trials. Nutrition reviews.
52. [52] Irwin et al., 2019. Effects of acute caffeine consumption following sleep loss on cognitive, physical, occupational and driving performance: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews.
53. [53] Irwin et al., 2020. Effects Of Acute Caffeine Ingestion Following A Period Of Sleep Loss On Cognitive And Physical Performance: A Systematic Review And Meta-analysis. Journal is not defined within the JOURNAL database.
54. [54] Zajac et al., 2025. The Effect of Ergothioneine Supplementation on Cognitive Function, Memory, and Sleep in Older Adults with Subjective Memory Complaints: A Randomized Placebo-Controlled Trial. Nutraceuticals.
55. [55] Ishimoto & Kato, 2022. Ergothioneine in the brain. FEBS Letters.
56. [56] Takhor & Phan, 2025. The role of Ergothioneine in cognition and age-related neurodegenerative disease: a systematic review. InflammoPharmacology.
57. [57] Scholey et al., 2010. Consumption of cocoa flavanols results in acute improvements in mood and cognitive performance during sustained mental effort. Journal of Psychopharmacology.
58. [58] Sokolov et al., 2013. Chocolate and the brain: Neurobiological impact of cocoa flavanols on cognition and behavior. Neuroscience and Biobehavioral Reviews.
59. [59] Massee et al., 2015. The acute and sub-chronic effects of cocoa flavanols on mood, cognitive and cardiovascular health in young healthy adults: a randomized, controlled trial. Frontiers in Pharmacology.
60. [60] Shah et al., 2013. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease. Alzheimer's Research & Therapy.
61. [61] Onakpoya & Heneghan, 2017. The efficacy of supplementation with the novel medical food, Souvenaid, in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials. Nutritional neuroscience.
62. [62] Cheah et al., 2021. Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis. PLoS ONE.
63. [63] Arumugam et al., 2024. Effects of Ashwagandha (Withania Somnifera) on stress and anxiety: A systematic review and meta-analysis. Explore.
64. [64] Marchi et al., 2025. The effect of Withania somnifera (Ashwagandha) on mental health symptoms in individuals with mental disorders: systematic review and meta-analysis. BJPsych Open.
65. [65] Kale et al., 2024. Safety and Efficacy of Ashwagandha Root Extract on Cognition, Energy and Mood Problems in Adults: Prospective, Randomized, Placebo-Controlled Study. Journal of Psychoactive Drugs.
66. [66] Bulman et al., 2025. The effects of L-theanine consumption on sleep outcomes: A systematic review and meta-analysis. Sleep Medicine Reviews.
67. [67] Williams et al., 2019. The Effects of Green Tea Amino Acid L-Theanine Consumption on the Ability to Manage Stress and Anxiety Levels: a Systematic Review. Plant Foods for Human Nutrition.
68. [68] Hidese et al., 2019. Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. Nutrients.
69. [69] Payne et al., 2025. Effects of Tea (Camellia sinensis) or its Bioactive Compounds l-Theanine or l-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrition reviews.
70. [70] Cotter et al., 2025. Examining the effect of L-theanine on sleep: a systematic review of dietary supplementation trials. Nutritional neuroscience.
71. [71] Hausenblas et al., 2024. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial. Sleep medicine: X.
72. [72] Kowalczyk et al., 2025. Magnesium and Mental Health: A Review of Its Role in Anxiety, Sleep Disorders and Depression. Journal of Education, Health and Sport.
73. [73] Mah & Pitre, 2021. Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis. BMC Complementary Medicine and Therapies.
74. [74] Lopresti & Smith, 2026. The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial. Frontiers in Nutrition.
75. [75] Chen et al., 2024. Magnesium and Cognitive Health in Adults: A Systematic Review and Meta-Analysis. Advances in Nutrition.
76. [76] Schuster et al., 2025. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nature and Science of Sleep.
77. [77] Soh et al., 2023. The effect of glycine administration on the characteristics of physiological systems in human adults: A systematic review. GeroScience.
78. [78] Bannai & Kawai, 2012. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. Journal of Pharmacological Sciences.
79. [79] Tuominen et al., 2005. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research.
80. [80] Ei et al., 2000. Neuroprotective Effects of Glycine for Therapy of Acute Ischaemic Stroke. Cerebrovascular Diseases.
81. [81] Hepsomali et al., 2020. Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review. Frontiers in Neuroscience.
82. [82] 外薗 & ほか, 2016. 疲労感や睡眠の問題を自覚している勤労者におけるGABA 含有食品の気分・感情および睡眠の質に与える影響―二重盲検無作為化比較試験―.
83. [83] 外薗 & ほか, 2018. 健常成人におけるGABA 経口摂取が睡眠に与える影響―無作為化二重盲検プラセボ対照クロスオーバー試験―.
84. [84] Guimarães et al., 2024. GABA Supplementation, Increased Heart-Rate Variability, Emotional Response, Sleep Efficiency and Reduced Depression in Sedentary Overweight Women Undergoing Physical Exercise: Placebo-Controlled, Randomized Clinical Trial. Journal of Dietary Supplements.
85. [85] Altınok et al., 2023. The effects of gamma-aminobutyric acid (GABA) on working memory and attention: A randomised, double-blind, placebo-controlled, crossover trial. bioRxiv.
86. [86] Cao et al., 2025. Effects of taurine supplementation on cognitive function: a systematic review and meta-analysis of randomised controlled trials. International Journal of Food Science and Nutrition.
87. [87] Moore et al., 2026. Cognitive Effects of Taurine and Related Sulphur-Containing Amino Acids: A Systematic Review of Human Trials and Considerations for Plant-Based Dietary Transitions. Foods.
88. [88] Salanitro et al., 2022. Efficacy on sleep parameters and tolerability of melatonin in individuals with sleep or mental disorders: a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews.
89. [89] Mdluli et al., 2025. Melatonin for sleep and cognitive outcomes in older adults with cognitive impairment: a meta-analysis of randomised controlled trials. Age and Ageing.
90. [90] Li et al., 2025. The Impact of 5-Hydroxytryptophan Supplementation on Cognitive Function and Mood in Singapore Older Adults: A Randomized Controlled Trial. Nutrients.
91. [91] Sutanto et al., 2024. The impact of 5-hydroxytryptophan supplementation on sleep quality and gut microbiota composition in older adults: A randomized controlled trial. Clinical Nutrition.
92. [92] Birdsall, 1998. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Alternative medicine review : a journal of clinical therapeutic.
93. [93] Moharir & Johns, 2003. 5-HTP for Improved Sleep, Mood and Weight Loss.
94. [94] Javelle et al., 2019. Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis. Nutrition reviews.
95. [95] Adekunle & Balogun, 2025. Tryptophan and HTP Supplementation in the Treatment of Cognitive and Mood Disorders: A Systematic Review and Meta-Analysis. Journal of Gynecological & Obstetrical Research.
96. [96] Meloni et al., 2021. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson’s disease. Sleep and Breathing.
97. [97] Shaw et al., 2001. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Systematic Reviews.
98. [98] Kikuchi et al., 2020. A systematic review of the effect of L-tryptophan supplementation on mood and emotional functioning. Journal of Dietary Supplements.
99. [99] Drabczyk et al., 2025. Tryptophan: The Molecular Key to Unlocking Superior Sleep, Mood Enhancement and Athletic Recovery. Journal of Education, Health and Sport.
100. [100] Sutanto et al., 2021. The impact of tryptophan supplementation on sleep quality: a systematic review, meta-analysis, and meta-regression. Nutrition reviews.
101. [101] Dalfsen & Markus, 2019. The serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the sleep-promoting effects of tryptophan: A randomized placebo-controlled crossover study. Journal of Psychopharmacology.
102. [102] Asante-Odame, 2015. How Safe and Effective Is Tryptophan in Improving Sleep in Healthy Individuals With Mild Sleep Disorders.
103. [103] Han et al., 2024. New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms. Phytotherapy Research.
104. [104] Ghaderi et al., 2020. The effects of saffron (Crocus sativus L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials. Complementary Therapies in Medicine.
105. [105] Lopresti et al., 2025. An examination into the effects of a saffron extract (affron®) on mood and general wellbeing in adults experiencing low mood: a randomised, double-blind, placebo-controlled trial. Journal of NutriLife.
106. [106] Lopresti et al., 2021. An investigation into an evening intake of a saffron extract (affron®) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study. Sleep Medicine.
107. [107] Kella et al., 2017. a ff ron ® a novel sa ff ron extract ( Crocus sativus L . ) improves mood in healthy adults over 4 weeks in a double-blind , parallel , randomized , placebo-controlled clinical trial.
108. [108] Avgerinos et al., 2020. Effects of saffron (Crocus Sativus L) on cognitive function. A systematic review of RCTs. Neurological Sciences.
109. [109] Bent et al., 2006. Valerian for sleep: a systematic review and meta-analysis. American Journal of Medicine.
110. [110] Maru et al. VALERIANA OFFICINALIS: A COMPREHENSIVE REVIEW ON ITS EFFICACY IN TREATING SLEEP DISORDERS.
111. [111] Fernández-San-Martín et al., 2010. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Medicine.
112. [112] Stevinson & Ernst, 2000. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Medicine.
113. [113] Taibi et al., 2007. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Medicine Reviews.
114. [114] Shinjyo et al., 2020. Valerian Root in Treating Sleep Problems and Associated Disorders—A Systematic Review and Meta-Analysis. Journal of Evidence-Based Integrative Medicine.
115. [115] Ghazizadeh et al., 2021. The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta‐analysis. Phytotherapy Research.
116. [116] Oliveira et al., 2025. Unraveling the Effects of Melissa officinalis L. on Cognition and Sleep Quality: A Narrative Review. International Journal of Molecular Sciences.
117. [117] Kennedy et al., 2002. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacology, Biochemistry and Behavior.
118. [118] Soltanpour et al., 2019. Effects of Melissa officinalis on anxiety and sleep quality in patients undergoing coronary artery bypass surgery: A double-blind randomized placebo controlled trial. European Journal of Integrative Medicine.
119. [119] Janda et al., 2020. Passiflora incarnata in Neuropsychiatric Disorders—A Systematic Review. Nutrients.
120. [120] Lee et al., 2019. Effects of Passiflora incarnata Linnaeus on polysomnographic sleep parameters in subjects with insomnia disorder: a double-blind randomized placebo-controlled study. International Clinical Psychopharmacology.
121. [121] Kaźmierczyk et al., 2024. Passiflora incarnata as an Adjunctive Treatment for Anxiety and Sleep Disorders. Quality in Sport.
122. [122] Ngan & Conduit, 2011. A Double‐blind, Placebo‐controlled Investigation of the Effects of Passiflora incarnata (Passionflower) Herbal Tea on Subjective Sleep Quality. Phytotherapy Research.
123. [123] Miroddi et al., 2013. Passiflora incarnata L.: ethnopharmacology, clinical application, safety and evaluation of clinical trials. Journal of Ethnopharmacology.
124. [124] Möller et al., 2017. Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. European Archives of Psychiatry and Clinical Neuroscience.
125. [125] Kasper et al., 2010. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. International Clinical Psychopharmacology.
126. [126] Yap et al., 2019. Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis. Scientific Reports.
127. [127] Kasper, 2013. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. International journal of psychiatry in clinical practice.
128. [128] Juánez, 2012. Hops (Humulus lupulus L.) and Beer: Benefits on the Sleep. Journal of sleep disorders and therapy.
129. [129] Brattström, 2009. Humulus lupulus (hops), is there any evidence for central nervous effects related to sleep?.
130. [130] Lee et al., 2024. Sleep-enhancing effect of Hongcheon-hop (Humulus lupulus L.) extract containing xanthohumol and humulone through GABAA receptor. Journal of Ethnopharmacology.
131. [131] Koetter et al., 2006. Effects of hops on clinical efficacy of a valerian-hops-extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Planta Medica.
132. [132] Chang et al., 2024. The impact of Alpha-s1 Casein hydrolysate on chronic insomnia: A randomized, double-blind controlled trial. Clinical Nutrition.
133. [133] Phing & Chee, 2019. EFFECTS OF ALPHA-S1-CASEIN TRYPTIC HYDROLYSATE AND L-THEANINE ON SLEEP DISORDER AND PSYCHOLOGICAL COMPONENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. Malaysian Journal of Public Health Medicine.
134. [134] Kazemi et al., 2024. Effects of chamomile (Matricaria chamomilla L.) on sleep: A systematic review and meta-analysis of clinical trials. Complementary Therapies in Medicine.
135. [135] Hieu et al., 2019. Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: A systematic review and meta‐analysis of randomized trials and quasi‐randomized trials. Phytotherapy Research.
136. [136] Ooi et al., 2018. Kava for Generalized Anxiety Disorder: A Review of Current Evidence. Journal of Alternative and Complementary Medicine.
137. [137] Sarris et al., 2011. Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology. Australian and New Zealand journal of psychiatry (Print).
138. [138] Mrnjavac, 2012. Is Kava (Piper Methysticum) Safe and Effective for Reducing Anxiety in Adult Patients 18-65?.
139. [139] Pittler & Ernst, 2003. Kava extract versus placebo for treating anxiety. Cochrane Database of Systematic Reviews.
140. [140] Konstantinos & Heun, 2020. The effects of Rhodiola Rosea supplementation on depression, anxiety and mood – A Systematic Review. Global Psychiatry.
141. [141] Ćmil et al., 2025. RHODIOLA ROSEA AS A NATURAL ADAPTOGEN: A REVIEW OF ITS EFFECTS ON STRESS REDUCTION, MOOD ENHANCEMENT, AND COGNITIVE FUNCTION. International Journal of Innovative Technologies in Social Science.
142. [142] Hung et al., 2011. The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine.
143. [143] Ishaque et al., 2012. Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complementary and Alternative Medicine.
144. [144] Abboud, 2022. Vitamin D Supplementation and Sleep: A Systematic Review and Meta-Analysis of Intervention Studies. Nutrients.
145. [145] Mirzaei-Azandaryani et al., 2022. The effect of vitamin D on sleep quality: A systematic review and meta-analysis. Nutrition and Health.
146. [146] Jamilian et al., 2019. The effects of vitamin D supplementation on mental health, and biomarkers of inflammation and oxidative stress in patients with psychiatric disorders: A systematic review and meta-analysis of randomized controlled trials. Progress in Neuro-psychopharmacology and Biological Psychiatry.
147. [147] Traina, 2016. The neurobiology of acetyl-L-carnitine. Frontiers in Bioscience.
148. [148] Pettegrew et al., 2000. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Molecular Psychiatry.
149. [149] Veronese et al., 2017. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosomatic Medicine.
150. [150] Montgomery et al., 2003. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. International Clinical Psychopharmacology.
151. [151] Sarmiento et al., 2016. Coenzyme Q10 Supplementation and Exercise in Healthy Humans: A Systematic Review. Current drug metabolism.
152. [152] Magalhães et al., 2025. Effects of Coenzyme Q10 Supplementation on Depressive Symptoms and Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Psychopharmacology.
153. [153] Akwan et al., 2025. The effect of coenzyme Q10 supplementation on depressive symptoms and anxiety: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology.
154. [154] Xie et al., 2025. Current study on Pyrroloquinoline quinone (PQQ) therapeutic role in neurodegenerative diseases. Molecular Biology Reports.
155. [155] Nakano et al., 2012. Effects of Oral Supplementation with Pyrroloquinoline Quinone on Stress, Fatigue, and Sleep. Functional Foods in Health and Disease.
156. [156] Shiojima et al., 2022. Safety and Efficacy of a Novel Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Functions in Healthy Volunteers: A Clinical Investigation. The FASEB Journal.
157. [157] Prokopidis et al., 2022. Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials. Nutrition reviews.
158. [158] Mińkowski et al., 2026. Creatine supplementation beyond skeletal muscles: cognitive and neuroprotective effects and underlying mechanisms – a narrative review. Quality in Sport.
159. [159] Xu et al., 2024. The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis. Frontiers in Nutrition.
160. [160] McMorris et al., 2006. Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol. Psychopharmacology.
161. [161] Maaoui et al., 2025. Effects of Creatine Monohydrate Loading on Sleep Metrics, Physical Performance, Cognitive Function, and Recovery in Physically Active Men: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Nutrients.
162. [162] Fares et al., 2026. The Effect of Creatine Monohydrate on Mental Disorders: A Systematic Review of Randomized Controlled Trials: Effet du monohydrate de créatine sur les troubles mentaux : examen systématique des essais contrôlés à répartition aléatoire. Canadian journal of psychiatry. Revue canadienne de psychiatrie.
163. [163] Walczak et al., 2024. Effect of creatine supplementation on cognitive function and mood. Journal of Education, Health and Sport.
164. [164] Avgerinos et al., 2019. Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer’s disease. A systematic review and meta-analysis of human studies. Ageing Research Reviews.
165. [165] Castro et al., 2023. Medium-chain fatty acids for the prevention or treatment of Alzheimer's disease: a systematic review and meta-analysis. Nutrition reviews.
166. [166] Giannos et al., 2022. Medium-chain triglycerides may improve memory in non-demented older adults: a systematic review of randomized controlled trials. BMC Geriatrics.
167. [167] Meer & Fischer, 2024. Medium-Chain Triglycerides (MCTs) for the Symptomatic Treatment of Dementia-Related Diseases: A Systematic Review. Journal of Nutrition and Metabolism.
168. [168] Rebello et al., 2015. Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: A randomized controlled trial. BBA Clinical.
169. [169] Ashton et al., 2020. The effects of medium chain triglyceride (MCT) supplementation using a C8:C10 ratio of 30:70 on cognitive performance in healthy young adults. Physiology and Behavior.
170. [170] Xu et al., 2019. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4-/-: A double-blind, randomized, placebo-controlled crossover trial. Clinical Nutrition.
171. [171] Bonnechere et al., 2026. The effect of exogenous ketone bodies on cognition across health and disease: a systematic review and meta-analysis. Frontiers in Nutrition.
172. [172] Falkenhain et al., 2022. Effects of Exogenous Ketones on Blood β-OHB and Glucose: A Systematic Review and Meta-Analysis. Current Developments in Nutrition.
173. [173] Bonnechère et al., 2025. The Effect of Exogenous Ketone Bodies on Cognition in Patients with Mild Cognitive Impairment, Alzheimer’s Disease and in Healthy Adults: A Systematic Review and Meta-Analysis. medRxiv.
174. [174] White et al., 2021. A Systematic Review of Intravenous β-Hydroxybutyrate Use in Humans – A Promising Future Therapy?. Frontiers in Medicine.
175. [175] Chintapenta et al., 2017. A Brief Review of Caprylidene (Axona) and Coconut Oil as Alternative Fuels in the Fight Against Alzheimer's Disease. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.
176. [176] Henderson et al., 2020. A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer’s Disease. Journal of Alzheimer's Disease.
177. [177] Ohnuma et al., 2016. Clinical Interventions in Aging Dovepress. Clinical Interventions in Aging.
178. [178] Song et al., 2022. A systematic review and meta-analysis of cognitive and behavioral tests in rodents treated with different doses of D-ribose. Frontiers in Aging Neuroscience.
179. [179] Weiss, 2025. Vitamin B3 Ameliorates Sleep Duration and Quality in Clinical and Pre-Clinical Studies. Nutrients.
180. [180] Wu et al., 2025. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine.
181. [181] Santangelo et al., 2022. Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease. The American journal of geriatric psychiatry.
182. [182] Wu et al., 2025. Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment. Alzheimer's & Dementia.
183. [183] Elhassan et al., 2019. Nicotinamide riboside augments the human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures in aged subjects: a placebo-controlled, randomized trial. bioRxiv.
184. [184] Braidy & Liu, 2020. Can nicotinamide riboside protect against cognitive impairment?. Current opinion in clinical nutrition and metabolic care.
185. [185] Dewi et al., 2024. EFFICACY OF NICOTINAMIDE MONONUCLEOTIDE SUPPLEMENTATION (NMN) IN BLOOD NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) FOR ANTI-AGING IN ADULTS: A SYSTEMATIC REVIEW. Journal of advanced research in Medical and Health science.
186. [186] Gao et al., 2023. Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial. Trials.
187. [187] Morifuji et al., 2024. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience.
188. [188] Wang et al., 2024. Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-Aged and Elderly: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Pharmaceutical Biotechnology.
189. [189] Wen et al., 2024. Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials. Cureus.
190. [190] Rennie et al., 2015. Nicotinamide and neurocognitive function. Nutritional neuroscience.
191. [191] Fricker et al., 2018. The Influence of Nicotinamide on Health and Disease in the Central Nervous System. International Journal of Tryptophan Research.
192. [192] Liu et al., 2012. Nicotinamide Forestalls Pathology and Cognitive Decline in Alzheimer Mice: Evidence for Improved Neuronal Bioenergetics and Autophagy Procession. Neurobiology of Aging.
193. [193] Martin et al., 2019. Neurocognitive Function and Quality of Life Outcomes in the ONTRAC Study for Skin Cancer Chemoprevention by Nicotinamide. Geriatrics.
194. [194] Prousky, 2010. An N-of-1 Placebo-Controlled Trial in Clinical Practice: Testing the Effectiveness of Oral Niacinamide (Nicotinamide) for the Treatment of Anxiety.
195. [195] Seddon et al., 2019. Effects of Curcumin on Cognitive Function—A Systematic Review of Randomized Controlled Trials. Exploratory Research and Hypothesis in Medicine.
196. [196] Scholey et al., 2020. Curcumin improves hippocampal function in healthy older adults: a three month randomised controlled trial. Proceedings of the Nutrition Society.
197. [197] Sarraf et al., 2019. Short-term curcumin supplementation enhances serum brain-derived neurotrophic factor in adult men and women: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutrition Research.
198. [198] Yuan et al., 2025. Potential therapeutic benefits of curcumin in depression or anxiety induced by chronic diseases: a systematic review of mechanistic and clinical evidence. Frontiers in Pharmacology.
199. [199] Ng et al., 2017. Clinical Use of Curcumin in Depression: A Meta-Analysis. Journal of the American Medical Directors Association.
200. [200] Marx et al., 2018. Effect of resveratrol supplementation on cognitive performance and mood in adults: a systematic literature review and meta-analysis of randomized controlled trials. Nutrition reviews.
201. [201] Koushki et al., 2018. Effect of Resveratrol Supplementation on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics.
202. [202] Saito et al., 2025. Sulforaphane as a potential therapeutic agent: a comprehensive analysis of clinical trials and mechanistic insights. Journal of Nutritional Science.
203. [203] Kikuchi et al., 2021. Effects of glucoraphanin-rich broccoli sprout extracts on sleep quality in healthy adults: An exploratory study. Journal of Functional Foods.
204. [204] Peng et al., 2024. S-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: An updated systematic review and meta-analysis. General Hospital Psychiatry.
205. [205] Sarris et al., 2019. S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. Psychopharmacology.
206. [206] Nelson, 2010. S-adenosyl methionine (SAMe) augmentation in major depressive disorder. American Journal of Psychiatry.
207. [207] Limveeraprajak et al., 2024. Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta- analysis. Progress in Neuro-psychopharmacology and Biological Psychiatry.
208. [208] Galizia et al., 2016. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database of Systematic Reviews.
209. [209] Baden et al., 2024. S-Adenosylmethionine (SAMe) for Central Nervous System Health: A Systematic Review. Nutrients.
210. [210] Nelson, 2012. The evolving story of folate in depression and the therapeutic potential of l-methylfolate. American Journal of Psychiatry.
211. [211] Altaf et al., 2021. Folate as adjunct therapy to SSRI/SNRI for Major Depressive Disorder: Systematic Review & Meta-analysis. Complementary Therapies in Medicine.
212. [212] Khalili et al., 2022. The effects of folic acid supplementation on depression in adults: a systematic review and meta-analysis of randomized controlled trials. Nutrition & Food Science.
213. [213] Roberts et al., 2018. Caveat emptor: Folate in unipolar depressive illness, a systematic review and meta-analysis. Journal of Psychopharmacology.
214. [214] Taylor et al., 2004. Folate for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Psychopharmacology.
215. [215] Markun et al., 2021. Effects of Vitamin B12 Supplementation on Cognitive Function, Depressive Symptoms, and Fatigue: A Systematic Review, Meta-Analysis, and Meta-Regression. Nutrients.
216. [216] Alzahrani, 2024. Assessment of Vitamin B12 Efficacy on Cognitive Memory Function and Depressive Symptoms: A Systematic Review and Meta-Analysis. Cureus.
217. [217] Zhou et al., 2023. Vitamin B12 supplementation improves cognitive function in middle aged and elderly patients with cognitive impairment. Nutrición Hospitalaria.
218. [218] Rossignol & Frye, 2021. The Effectiveness of Cobalamin (B12) Treatment for Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine.
219. [219] Malouf & Evans, 2003. The effect of vitamin B6 on cognition. Cochrane Database of Systematic Reviews.
220. [220] HaticeSağlam, 2020. P5P (B6) Focused Genetics, Epigenetic Glance to Health. Journal of US-China Medical Science.
221. [221] Malouf & Evans, 2003. Vitamin B6 for cognition. Cochrane Database of Systematic Reviews.
222. [222] Plevin & Galletly, 2020. The neuropsychiatric effects of vitamin C deficiency: a systematic review. BMC Psychiatry.
223. [223] Yosaee et al., 2021. The effect of vitamin C supplementation on mood status in adults: a systematic review and meta-analysis of randomized controlled clinical trials. General Hospital Psychiatry.
224. [224] Wang et al., 2013. Effects of vitamin C and vitamin D administration on mood and distress in acutely hospitalized patients. American Journal of Clinical Nutrition.
225. [225] Oliveira, 2014. O papel da vitamina C na ansiedade e memória em dois estudos : na cognição em humanos escolarizados e no comportamento de animais crescidos em ambiente enriquecido.
226. [226] Agh et al., 2022. The Effect of Zinc Supplementation on Circulating Levels of Brain-Derived Neurotrophic Factor (BDNF): A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Preventive Medicine.
227. [227] Yosaee et al., 2020. Zinc in depression: From development to treatment: A comparative/ dose response meta-analysis of observational studies and randomized controlled trials. General Hospital Psychiatry.
228. [228] Hosseini et al., 2020. Zinc supplementation is associated with a reduction in serum markers of inflammation and oxidative stress in adults: A systematic review and meta-analysis of randomized controlled trials. Cytokine.
229. [229] Warthon-Medina et al., 2015. Zinc intake, status and indices of cognitive function in adults and children: a systematic review and meta-analysis. European Journal of Clinical Nutrition.
230. [230] Salama et al., 2025. Safety and efficacy of selenium in improving the outcomes of stroke patients: a systematic review and meta-analysis with GRADE system. The Egyptian Journal of Neurology Psychiatry and Neurosurgery.
231. [231] Fiani et al., 2025. Psychiatric and cognitive outcomes of iron supplementation in non-anemic children, adolescents, and menstruating adults: a meta-analysis and systematic review. Neuroscience and Biobehavioral Reviews.
232. [232] Spence et al., 2020. The impact of brain iron accumulation on cognition: A systematic review. PLoS ONE.
233. [233] Gordon et al., 2009. Iodine supplementation improves cognition in mildly iodine-deficient children. American Journal of Clinical Nutrition.
234. [234] Taylor et al., 2014. Therapy of endocrine disease: Impact of iodine supplementation in mild-to-moderate iodine deficiency: systematic review and meta-analysis. European Journal of Endocrinology.
235. [235] Dineva et al., 2020. Systematic review and meta-analysis of the effects of iodine supplementation on thyroid function and child neurodevelopment in mildly-to-moderately iodine-deficient pregnant women. American Journal of Clinical Nutrition.
236. [236] Shrayner et al., 2025. Glutathione: a key molecule of redox homeostasis and its potential for nutritional and metabolic regulation. a review of the literature. Molekulyarnaya Meditsina (Molecular medicine).
237. [237] Sekhar et al., 2024. IMPROVING GLUTATHIONE, MITOCHONDRIA, INFLAMMATION, AND COGNITIVE DECLINE: A PILOT CLINICAL TRIAL OF GLYNAC IN AGING. Innovation in aging.
238. [238] Nasiri et al., 2025. Glutathione and N-acetylcysteine in TB management. The International Journal of Tuberculosis and Lung Disease.
239. [239] Deepmala et al., 2015. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neuroscience and Biobehavioral Reviews.
240. [240] Skvarc et al., 2017. The effect of N-acetylcysteine (NAC) on human cognition – A systematic review. Neuroscience and Biobehavioral Reviews.
241. [241] Peng et al., 2024. Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis. General Hospital Psychiatry.
242. [242] Śliwka et al., 2025. Psychobiotics in Depression: Sources, Metabolites, and Treatment—A Systematic Review. Nutrients.
243. [243] Dib et al., 2021. Probiotics for the treatment of depression and anxiety: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN.
244. [244] Marotta et al., 2019. Effects of Probiotics on Cognitive Reactivity, Mood, and Sleep Quality. Frontiers in Psychiatry.
245. [245] Sequeira et al., 2022. Effect of Probiotics on Psychiatric Symptoms and Central Nervous System Functions in Human Health and Disease: A Systematic Review and Meta-Analysis. Nutrients.
246. [246] Tabrizi et al., 2019. Psychobiotics, as Promising Functional Food to Patients with Psychological Disorders: A Review on Mood Disorders, Sleep, and Cognition. NeuroQuantology.
247. [247] Krug et al., 2019. The Effect of Prebiotic Consumption on the Gastrointestinal Microbiota of Healthy Adults: A Randomized, Controlled, Crossover Trial (P20-015-19). Current Developments in Nutrition.
248. [248] Zhang et al., 2023. Prebiotics modulate the microbiota–gut–brain axis and ameliorate cognitive impairment in APP/PS1 mice. European Journal of Nutrition.
249. [249] Ekin et al., 2023. 0201 Prebiotic Diet Impact on Cognitive Performance, Sleepiness, and Mood During Combined Sleep Restriction and Circadian Misalignment. Sleep.
250. [250] Mysonhimer et al., 2023. Prebiotic Consumption Alters Microbiota but Not Biological Markers of Stress and Inflammation or Mental Health Symptoms in Healthy Adults: A Randomized, Controlled, Crossover Trial. Journal of NutriLife.
251. [251] Leyrolle et al., 2021. Prebiotic effect on mood in obese patients is determined by the initial gut microbiota composition: a randomized, controlled trial. Brain, behavior, and immunity.
252. [252] 上﨑 & ほか, 2018. ラクトフェリン含有食品が睡眠不良者の睡眠感，気分状態および腸内環境に与える効果―無作為化プラセボ対照二重盲検比較試験―.
253. [253] Yami et al., 2023. The immunomodulatory effects of lactoferrin and its derived peptides on NF‐κB signaling pathway: A systematic review and meta‐analysis. Immunity, Inflammation and Disease.
254. [254] Miyakawa et al., 2020. Effects of Lactoferrin on Sleep Conditions in Children Aged 12–32 Months: A Preliminary, Randomized, Double-Blind, Placebo-Controlled Trial. Nature and Science of Sleep.
255. [255] Berthon et al., 2022. Effect of Lactoferrin Supplementation on Inflammation, Immune Function, and Prevention of Respiratory Tract Infections in Humans: A Systematic Review and Meta-analysis. Advances in Nutrition.
256. [256] Zarama et al., 2023. The Effect of Spermidine Supplementation on Cognitive Function in Adults: A Mini-Review. Principles and Practice of Clinical Research Journal.
257. [257] Gai, 2025. The beneficial effects of spermidine via autophagy: a systematic review. Theoretical and Natural Science.
258. [258] Schroeder et al., 2021. Dietary spermidine improves cognitive function. Cell Reports.
259. [259] Mancini et al., 2017. Green tea effects on cognition, mood and human brain function: A systematic review. Phytomedicine.
260. [260] Scholey et al., 2012. Acute neurocognitive effects of epigallocatechin gallate (EGCG). Appetite.
261. [261] Payne et al., 2024. The effects of tea (Camellia sinensis) or its bioactive compounds L-theanine or L-theanine plus caffeine on cognition, sleep, and mood in healthy participants: a systematic review and meta-analysis of randomised controlled trials. Proceedings of the Nutrition Society.
262. [262] Camfield et al., 2014. Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis. Nutrition reviews.
263. [263] Lorzadeh et al., 2025. The Effect of Anthocyanins on Cognition: A Systematic Review and Meta-analysis of Randomized Clinical Trial Studies in Cognitively Impaired and Healthy Adults. Current nutrition reports.
264. [264] Micek et al., 2025. The effect of anthocyanins and anthocyanin-rich foods on cognitive function: a meta-analysis of randomized controlled trials. GeroScience.
265. [265] Lorzadeh et al., 2023. The effect of anthocyanin intake on cognition: a systematic literature review and meta-analysis. Proceedings of the Nutrition Society.
266. [266] Dai et al., 2022. The neuropharmacological effects of magnolol and honokiol：a review of signal pathways and molecular mechanisms. Current Molecular Pharmacology.